...
首页> 外文期刊>Journal of clinical gastroenterology >40 mg Pantoprazole and 40 mg Esomeprazole Are Equivalent in the Healing of Esophageal Lesions and Relief from Gastroesophageal Reflux Disease-related Symptoms.
【24h】

40 mg Pantoprazole and 40 mg Esomeprazole Are Equivalent in the Healing of Esophageal Lesions and Relief from Gastroesophageal Reflux Disease-related Symptoms.

机译:40毫克Pan托拉唑和40毫克埃索美拉唑在治疗食管病变和缓解胃食管反流疾病相关症状方面是等效的。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND:: Proton pump inhibitors are regarded as the most effective class of acid suppressive medication for gastroesophageal reflux disease treatment. There is considerable interest regarding the dose equivalence between various proton pump inhibitors. GOALS:: To compare the efficacy of pantoprazole and esomeprazole with regard to healing and relief from gastroesophageal reflux disease-related symptoms. STUDY:: Multicenter, randomized, double-blind study. Patients with gastroesophageal reflux disease grades B/C (Los Angeles classification) received 40 mg pantoprazole daily (n = 113) or 40 mg esomeprazole daily (n = 114). Healing (endoscopy) and relief from gastroesophageal reflux disease-related symptoms (direct questioning) were assessed at first and final visit (after 4, 6, 8, or 10 weeks of treatment). RESULTS:: Overall healing in both treatment groups was 88% of patients (intention-to-treat population), 95% (pantoprazole), and 90% (esomeprazole) (per-protocol population); statistically, this indicates "at least equivalence" between treatments. Overall relief from gastroesophageal reflux disease-related symptoms was similar for pantoprazole (55%) and esomeprazole (51%, per-protoco). No correlation between healing and symptom relief was seen. The majority of reported adverse events were assessed as "not related" to the study drug. Pantoprazole and esomeprazole have comparably good safety and tolerability. CONCLUSION:: In patients with gastroesophageal reflux disease, 40 mg pantoprazole daily and 40 mg esomeprazole daily are equally effective for healing of esophageal lesions and relieving gastroesophageal reflux disease-related symptoms.
机译:背景:质子泵抑制剂被认为是治疗胃食管反流病最有效的抑酸药物。人们对各种质子泵抑制剂之间的剂量当量感兴趣。目标::比较pan托拉唑和埃索美拉唑在胃食管反流疾病相关症状的愈合和缓解方面的功效。研究::多中心,随机,双盲研究。胃食管反流疾病等级为B / C(洛杉矶分类)的患者每天接受40毫克pan托拉唑(n = 113)或每天40 mg埃索美拉唑(n = 114)。在首次和最终就诊时(治疗4、6、8或10周后)评估愈合(内窥镜检查)和胃食管反流疾病相关症状的缓解(直接询问)。结果:两个治疗组的总体治愈率分别为88%(意向治疗人群),95%(pan托拉唑)和90%(依索美拉唑)(按方案人群)。从统计学上讲,这表明治疗之间的“至少等效”。潘托拉唑(55%)和埃索美拉唑(51%,按原方案)从胃食管反流疾病相关症状的总体缓解情况相似。治愈与症状缓解之间没有相关性。大多数报告的不良事件被评估为与研究药物“无关”。 top托拉唑和埃索美拉唑具有相当好的安全性和耐受性。结论:在患有胃食管反流疾病的患者中,每天40 mg潘托拉唑和每天40 mg埃索美拉唑对食管病变的愈合和缓解与胃食管反流疾病相关的症状同样有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号